Key result
Early administration of corvitin before cardiac revascularization in ACS+ST patients preserved myocardial viability and prevented irreversible LV systolic dysfunction seen in 32% of control segments.
Why the study?
Does corvitin added to standard therapy before revascularization improve left ventricular systolic function in patients with ST-segment elevation acute coronary syndrome?
RCT (n=60)
Does corvitin added to standard therapy before revascularization improve left ventricular systolic function in patients with ST-segment elevation acute coronary syndrome?
Early administration of corvitin before revascularization in STEMI patients may preserve left ventricular systolic function and prevent post-reperfusion complications.
Answers are grounded in this paper and cite their sources.
May support pre-revascularization corvitin in STEMI to preserve LV function; extends RCT evidence for adjunctive cardioprotection.
Aim. To study effects of bioflavonoid quercetin (corvitin) on left ventricle (LV) systolic dysfunction in patients with acute coronary syndrome with ST segment elevation (ACS+ST) after cardiac revascularization. Material and methods. 60 patients with ACS+ST (44,2±1,3 y.o.) were examined. Patients were admitted to hospital within 6 hours after complaints beginning. Patients were randomized in two groups. 30 patients of group A had standard therapy and cardiac revascularization. 30 patients of group B received corvitin additionally to standard therapy before cardiac revascularization. Echocardiography initially and stress-echocardiography with dobutamine after status stabilization (at 8-10 days of disease) were performed. Results. Dobutamine test (with low and high doses) showed myocardial viability in patients of group B. Patients of group A had irreversible LV systolic dysfunction in 32 % of segments. Corvitin slowed down LV dilatation progression in patients with ACS+ST. It resulted in the end-diastolic and end-systolic indexes did not change within 10 days. The LV ejection fraction was more increased in patients of group B in comparison with patients of group A. Conclusion. The early corvitin prescribing has positive effects on LV systolic function and prevents post-reperfusion complications.
No takes yet. Share an insight, caveat, or question.
Alyavi et al. (2009) conducted an RCT in Acute coronary syndrome with ST segment elevation (ACS+ST) (n=60). Bioflavonoid quercetin (corvitin) vs. Standard therapy and cardiac revascularization was evaluated on Irreversible LV systolic dysfunction (in segments). Early administration of corvitin before cardiac revascularization in ACS+ST patients preserved myocardial viability and prevented irreversible LV systolic dysfunction seen in 32% of control segments.
Synapse has enriched 10 related papers. Consider them for comparative context: